肝细胞癌维甲酸α核受体的免疫组化研究和临床意义  

Immunohistochemical Study of RAR α in Hepatocellular Carcinoma and Their Clinical Significances

作　　者：束永前[1] 吴永金[1] 丁海[1] 

机构地区：[1]苏州医学院二附院 [2]南京大学医院

出　　处：《实用癌症杂志》1997年第3期186-188,共3页The Practical Journal of Cancer

摘　　要：作者对４２例原发性肝细胞癌（简称肝癌）的石蜡切片作维甲酸α核受体（ＲＡＲ－α）免疫组化研究。结果显示：使用免疫组化方法可以显示肝细胞癌细胞核上的ＲＡＲ－α分布情况。Ⅰ级肝癌ＲＡＲ－α阳性率为１１．５％±３．４％，Ⅱ级为２８．９％±２０．２％，Ⅲ级为３６．１％±１８．４％，Ⅳ级为４８．８％±３８．４％；ＲＡＲ－α阳性率水平与预后有关，生存≥６个月和＜６个月，ＲＡＲ－α阳性率差异显著（Ｐ＜０．０５）；ＲＡＲ－α阳性率的高低，与维甲酸治疗疗效有一定的关系。ＲＡＲ－α阳性率的表达水平可作为肝癌恶性度和预后判断的指标，为维甲酸治疗肝癌提供了客观依据。Forty two cases of hepatocellular carcinoma(HCC) were studied immunohistochemically by using monoclonal antibodies retinoic acid receptor α(RAR α) applied on parafin embedded tissue sections. The result suggested that we could show the cellular distribution of RAR α in HCC specimens by immunohistochemical staining with antibodies to RAR α applied on parafin embedded tissue sections. The expression rate of RAR α was 11.5%±3.4% in HCCs of grad Ⅰ,28.9%±20.2% in HCCs of grad Ⅱ,36.1%±18.4% in HCCs of grad Ⅲ. 48.8%±38.4% in HCCs of grad Ⅳ. There is distinct relationship between the survial and the expression rate of RAR α. The more expression rate of RAR α is, the shorter the survial is. RAR α expression levels may be used as a indicator to the degree of malignancy and evaluating prognosis of the disease and may serve as a potential marker to determine patient responsiveness to retinoic acid therapy.

关 键 词：肝细胞癌 维甲酸α核受体 肝肿瘤 免疫组织化学 

分 类 号：R735.7[医药卫生—肿瘤]